Mitral Regurgitation and Atrial Fibrillation: The Contribution of Impaired Left Atrial Appendage Function to Atrial Thrombogenesis by Pamukcu, Burak & Bitigen, Atilla
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
  
21 
Mitral Regurgitation and  
Atrial Fibrillation:  
The Contribution of Impaired  
Left Atrial Appendage Function  
to Atrial Thrombogenesis 
Burak Pamukcu1 and Atilla Bitigen2 
1Bayrampasa Medical Centre, Istanbul,  
2Medical Park Hospital, Fatih, Istanbul,  
Turkey 
1. Introduction 
1.1 Epidemiology of atrial fibrillation 
Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia which affects 1 to 2 % 
of the entire adult population [1].  Current studies indicate that the prevalence of AF will be 
doubled in a few decades [2]. As a major source of public health problem, atrial fibrillation 
increases the risk of stroke (up to 18 fold especially in patients with valvular AF), long term 
disability, hospitalizations, cardiovascular mortality and healthcare costs [3-4]. The 
prevalence of atrial fibrillation and its complications are more common among patients with 
rheumatic heart disease especially in patients with mitral stenosis and regurgitation. Stroke 
is one of the most common and disabling complication of atrial fibrillation. Recent studies 
indicated that age, presence of hypertension, diabetes, heart failure and/or previous stroke 
or transient ischemic attack (TIA) as pivotal contributor risk factors to generation of stroke 
in AF patients [5-8]. Although the presence of these factors increases the risk of stroke in 
non-valvular AF patients, the absolute risk of stroke is much higher in patients with 
valvular AF [9]. 
2. Mitral valve disease and atrial fibrillation 
In patients with rheumatic mitral regurgitation (MR) major anatomic changes comprise 
annular dilatation and prolapse of the anterior mitral valve leaflet due to elongation of 
chordae tendinea [10]. However, retractile fibrosis of leaflets and chordae tendinea that 
leads loss of coaptation is the main pathologic finding in patients with chronic rheumatic 
MR [11]. In the early phases of rheumatic disease the most frequent echocardiographic 
finding is the enlargement of left atrium in patients on sinus rhythm. However, paroxysmal 
or permanent atrial fibrillation ultimately affects 50% of patients within 10 years of 
www.intechopen.com
 
Atrial Fibrillation - Basic Research and Clinical Applications 
 
374 
diagnosis in sinus rhythm [12]. Left atrial enlargement causes impaired mitral apparatus 
function and loss of coaptation causes mitral regurgitation. On the other hand, left atrial 
enlargement contributes to the generation of atrial re-entry and atrial fibrillation. 
Progressive left atrial enlargement increases the risk of AF development. New onset AF 
occurs in 10 to 20% of patients with myocardial infarction due to ischemia of atria or sinus 
node [13]. Atrial fibrillation is more common among older and hypertensive patients with 
mitral regurgitation and enlarged left atria [13]. 
3. Left atrial appendage as a source of thrombi and stroke 
The left atrial appendage (LAA), a blind-ended complex structure that is embryologically 
distinct from the body of the left atrium, is been identified as the major source of cardiac 
systemic embolic events in patients with AF [14]. The atrium and the LAA compensate for 
the age-induced changes in LV diastolic properties by increasing active atrial contraction (a-
wave) [15]. An experimental study and a clinical study showed the presence of an inverse 
relationship between LA filling pressure and LAA emptying function (inverse correlation 
between capillary wedge pressure and LAA active emptying a-wave) [16, 17]. Due to its 
compliance, the LAA is acting as a modulator of LA pressure. 
It has been demonstrated that more than 15% of strokes originate from the heart, and 
especially from the LAA [18]. A recent study showed the presence of thrombi in the left 
atrial cavity in 1.9% of the AF patients. In the same study, the incidence of LAA thrombi was 
reported 6.6-fold that of left atrial cavity thrombi. Of note, AF was also determined in most 
of the patients with LAA thrombi [19].  
4. Left atrial appendage function in atrial fibrillation 
LAA has hemodynamic roles and contributes to atrial function. Impaired LAA function is 
been shown to lead increased thrombosis in left atrium [19]. 
Another previous study evaluated LAA function in 60 patients with severe rheumatic MR 
on both sinus rhythm and atrial fibrillation. Impaired LAA functions were determined in 
patients with severe mitral regurgitation having AF, whereas LAA was preserved in 
patients with normal sinus rhythm compared to controls [20]. Another study which aimed 
to compare LAA functions before and after percutaneous balloon mitral valvuloplasty 
(PBMV) by tissue wave Doppler imaging enrolled 20 patients with symptomatic rheumatic 
mitral stenosis [21]. LAA functions were evaluated by the measurement of; LAA late filling 
(LAALF) velocity, LAA late emptying (LAALE) velocity, and percent area change of the 
LAA [21]. No significant difference was reported in LAALF velocity and area percent 
change of the LAA after PBMV [21] while LAALE velocity was found increased after PBMV 
compared to baseline values (p=0.005). In the same study increased late emptying, systolic, 
and diastolic wave values were determined by tissue Doppler imaging after PBMV when 
compared to basal measurements (p=0.023, p=0.002, and p=0.002, respectively). Of note, 
significant improvement was determined in left atrial spontaneous echo-contrast after 
PBMV and LAA functions [21]. 
The functions of LAA have been evaluated in patients with severe rheumatic mitral 
regurgitation both in AF or sinus rhythm [22]. Impairment of LAA functions is been shown 
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to contribute to thrombogenic processes and it is been often determined among AF patients 
when compared to those in sinus rhythm. Recent studies indicated that the LAA flows were 
strongly affected by the type of atrial arrhythmia. For example, the average emptying flow 
velocity was found weaker in AF than in sinus rhythm, and it was found greater in atrial 
flutter than in AF [23].  
5. Markers of left atrial appendage function 
The role of different markers that can be associated with LAA function has been evaluated 
in recent studies. One of these studies investigated the expression of proteins associated 
with the cytoskeleton, energetic metabolism, and cardiac cytoprotection between left atrial 
appendages (LAA) and right atrial appendages (RAA) obtained from patients with mitral 
valve disease both in sinus rhythm and in permanent atrial fibrillation. Similar levels of 
protein expression is been reported both in RAA and LAA samples. However, expression 
of cardiac alpha-actin isotypes 1 and 2, tropomyosin alpha- and beta-chains, and myosin 
light chain embryonic muscle/atrial isoform in LAA from AF patients was found 
increased when compared to those from SR patients [24].  Another potential contributor to 
atrial remodelling, cardiac endothelin-1 (ET-1), is expressed as a response to wall stress 
and can promote myocyte hypertrophy and interstitial fibrosis [25]. Elevated atrial ET-1 
level is been found associated with increased LA size, AF prevalence, hypertension, and 
heart failure [25]. An association between ET-1 and atrial dilatation, fibrosis, and 
hypertrophy is been reported. Endothelin-1 is suggested as a contributing factor to AF 
persistence [25]. 
Although both mitral stenosis and MR are strongly associated with AF, the prevalence of AF 
in mitral stenosis patients is much higher than MR patients. Approximately 29% of the 
patients with isolated mitral stenosis develop AF while only 16% of the patents with isolated 
MR [26, 27]. 
6. Atrial remodelling in atrial fibrillation 
A recent study aimed to assess the relationship between atrial structural remodelling in 
AF patients with different types of mitral valve diseases [28]. The study recruited 24 
patients undergoing mitral valve surgery with different diagnoses. Left atrial appendage 
tissue samples were obtained from patients with mitral valve disease either in sinus 
rhythm or AF. Masson’s trichrome staining and immunohistochemical staining were 
performed to assess the extent of the fibrosis. The authors reported significantly increased 
fibrosis in patients with AF when compared to patients in sinus rhythm (p=0.023) [28]. 
The collagen volume fraction of fibrosis was also significantly increased in patients with 
mitral stenosis and atrial fibrillation when compared to patients with mitral regurgitation 
and atrial fibrillation (p=0.043) [28]. Collagen Type I levels were also significantly 
increased in AF patients with mitral stenosis when compared to patients with mitral 
regurgitation and AF (p=0.043). Of note, different collagen volume fraction of Matrix 
MetalloProteinases-2 (MMP2) was determined between the patients with mitral stenosis 
and sinus rhythm and patients with mitral stenosis and AF (p=0.001). The authors 
concluded that heart rhythm status and type of underlying mitral valve disease influence 
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atrial structural remodelling and different atrial structural remodelling may contribute to 
the development of AF [28]. 
The remodelling processes involving atrial fibrosis and atrial dilatation in AF patients also 
recruit angiotensin II mediated pathways and MMPs. There are evidences showing that 
patients with mitral stenosis and AF have significantly larger atria than patients with mitral 
stenosis but sinus rhythm [29]. Fibrosis was found increased in mitral stenosis patients in 
AF and SR in the left atria, but only in mitral stenosis patients with AF in the right atria. 
Furthermore, MMP-1 was reported to be down-regulated in left atria of mitral stenosis 
patients (p=0.02) both in sinus rhythm or AF [29]. Although there is no evidence showing 
that AF contributes to altered fibrosis or MMP-expression in the left atria, atrial remodelling 
appears to recruit changes in MMP-expression in patients with mitral valve disease either in 
sinus rhythm or AF [29]. 
Interestingly, mitral regurgitation can provide protective effects against left atrial blood 
stasis. The relationship between the severity of MR and thromboembolic risk has been 
clarified in patients with AF. A recent study indicated a protective effect of MR against 
thromboembolic risk over reducing LA blood stasis but only limited to patients with severe 
MR [30]. 
7. Mitral valve disease, atrial fibrillation and thrombosis 
The association between mitral valve disease and atrial fibrillation appears to constitute a 
vicious cycle. Different dynamics including changes in LAA functions affect the generation 
and persistence of atrial fibrillation. The severity of mitral valve regurgitation has pivotal 
influence on left atrial flow dynamics and LAA stasis which appears to be the major 
determinant of thrombus generation [31]. 
The mechanisms of thrombogenesis in patients with MR or aortic stenosis (AS) have been 
investigated in patients both in sinus rhythm and AF. Patients with MR or AS have been 
shown to have higher plasma fibrinogen levels when compared to healthy people and also 
lower plasma fibrin D-dimer levels suggesting decreased intravascular clotting has been 
reported [32]. Furthermore, the presence of immunoreactive von Willebrand factor (vWF) in 
the endocardial endothelium and its relationship to thrombogenesis in the human atrial 
appendage has been investigated [33]. Immunoreactive vWF in the endocardial 
endothelium was found increased in overloaded human atrial appendage, which was 
supposed to be a local predisposing factor for intraatrial thrombogenesis [33]. 
Another study investigated the contribution of plasma D-dimer levels to thrombogenesis in 
89 patients with mitral valve disease and 21 subjects with AF but normal valves, and 15 
healthy controls. Plasma D-dimer levels correlated with the embolic risk in mitral valve 
disease and non-valvular AF. The highest levels were found in patients with MS and AF and 
non-valvular AF. Severe MR decreased the D-dimer levels in MS and/or AF to control levels 
[34]. 
Transmitral pressure gradient is supposed to be another parameter that may influence the 
development of AF and thrombogenesis in patients with rheumatic heart disease  
[26]. However, patients’ age and left atrial diameter has been shown to be the major 
parameters that predict the occurrence of AF in patients with rheumatic heart disease  
[26]. 
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8. Conclusions 
Atrial fibrillation is the most common sustained cardiac arrhythmia and a severe public 
health problem. The prevalence of AF increases while the population is ageing. Mitral valve 
diseases, including mitral stenosis and mitral regurgitation increase AF prevalence. There 
are strong associations between severe mitral valve disease and the development of atrial 
fibrillation. Once atrial fibrillation starts it causes impaired LAA function and leads to 
increased intraatrial thrombogenesis. Left atrial thrombi and especially LAA thrombi are 
shown to be the commonest causes of embolic stroke. Management of this complex situation 
should comprise several steps including restoration of impaired LAA function, prevention 
of thrombogenesis and maintenance of sinus rhythm whenever it is feasible. 
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